Duvortuxizumab (INN[1]) is a chimeric/humanized monoclonal antibody designed for the treatment of B-cell malignancies.
[2] This drug was developed by Janssen Global Services.
[3] This monoclonal antibody–related article is a stub.
You can help Wikipedia by expanding it.